Oragenics (OGEN) Net Cash Flow (2010 - 2026)
Oragenics' (OGEN) quarterly Net Cash Flow came in at $1.7 million in Q1 2026, down 33.21% YoY from $2.6 million in Q1 2025, and up 157.51% on a QoQ basis from -$3.0 million in Q4 2025.
Oragenics (OGEN) Net Cash Flow (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Net Cash Flow data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Net Cash Flow fell 33.21% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (up 399.03% YoY) and the FY2025 annual result came in at $7.6 million, up 389.51% from the prior year.
- Net Cash Flow rose to $1.7 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $9.4 million in Q3 2025 to a low of -$5.9 million in Q1 2022.
- A 5-year average of -$1.0 million and a median of -$2.3 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 131.25% — and 2025, when it jumped 424.36%.
- Tracing OGEN's Net Cash Flow over 5 years: stood at -$2.5 million in 2022, then grew by 9.55% to -$2.3 million in 2023, then rose by 0.17% to -$2.3 million in 2024, then plunged by 30.25% to -$3.0 million in 2025, then soared by 157.51% to $1.7 million in 2026.
- The last three Net Cash Flow figures came in at $1.7 million (Q1 2026), -$3.0 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | -2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.26 Mn |
| Jun 30, 2026 | -2.26 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | -2.97 Mn |
| Dec 31, 2025 | -2.97 Mn |
| Sep 30, 2025 | 9.41 Mn |
| Sep 30, 2025 | 9.41 Mn |
| Jun 30, 2025 | -1.42 Mn |
| Jun 30, 2025 | -1.42 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | -2.28 Mn |
| Dec 31, 2024 | -2.28 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | -723,368.00 |
| Jun 30, 2024 | -723,368.00 |
| Mar 31, 2024 | -1.41 Mn |
| Mar 31, 2024 | -1.41 Mn |